-
公开(公告)号：EP2188276B1
公开(公告)日：2012-03-28
申请号：EP08786933.5
申请日：2008-08-06
发明人： CHEN, Shaoqing , HUBY, Nicholas, John, Silvester , KONG, Norman , MOLITERNI, John, Anthony , MORALES, Omar, Jose
IPC分类号： C07D403/06 , A61K31/4184 , A61P35/00
CPC分类号： C07D403/06
摘要： This invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK 2, protein kinases that are components of the MAP kinase signal transduction pathway. As such the compounds have anti-hyperproliferative cellular activity and are thus useful in the treatment of cell proliferative disorders, such as cancer.
-
公开(公告)号：EP2188276A1
公开(公告)日：2010-05-26
申请号：EP08786933.5
申请日：2008-08-06
发明人： CHEN, Shaoqing , HUBY, Nicholas, John, Silvester , KONG, Norman , MOLITERNI, John, Anthony , MORALES, Omar, Jose
IPC分类号： C07D403/06 , A61K31/4184 , A61P35/00
CPC分类号： C07D403/06
摘要： This invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK 2, protein kinases that are components of the MAP kinase signal transduction pathway. As such the compounds have anti-hyperproliferative cellular activity and are thus useful in the treatment of cell proliferative disorders, such as cancer.
-
公开(公告)号：EP2234982A1
公开(公告)日：2010-10-06
申请号：EP08864818.3
申请日：2008-12-10
发明人： CHEN, Shaoqing , HUBY, Nicholas, John, Silvester , KONG, Norman , MOLITERNI, John, Anthony , MORALES, Omar, Jose
IPC分类号： C07D233/74 , C07D233/78 , C07D417/14 , A61K31/4166 , A61P35/00
CPC分类号： C07D233/74 , C07D233/78 , C07D417/14
摘要： The present invention relates to compounds of the formula (I) methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
-
4.发明授权AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY 有权阿米德黄嘌呤糖异生调控作用取代衍生物
公开(公告)号：EP1515972B1
公开(公告)日：2009-05-13
申请号：EP03735559.1
申请日：2003-06-05
发明人： DUNTEN, Pete, William , FOLEY, Louise, Helen , HUBY, Nicholas, John, Silvester , PIETRANICO-COLE, Sherrie, Lynn , YUN, Weiya
IPC分类号： C07D473/02 , A61K31/52 , A61P3/10
CPC分类号： C07D473/04 , C07D473/02 , C07D473/06
摘要： The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R , R and R are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
-
公开(公告)号：EP1791837B1
公开(公告)日：2009-08-19
申请号：EP05784418.5
申请日：2005-09-15
发明人： GOODNOW, Robert, Alan, Jr. , HUBY, Nicholas, John, Silvester , KONG, Norman , MCDERMOTT, Lee, Apostle , MOLITERNI, John, Anthony , ZHANG, Zhuming
IPC分类号： C07D417/12 , C07D417/14 , A61K31/427 , A61P35/00
CPC分类号： C07D417/14 , C07D417/12
摘要： The present invention relates to compounds of the formula (I) which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
-
6.发明授权
公开(公告)号：EP1599477B1
公开(公告)日：2008-01-30
申请号：EP04710346.0
申请日：2004-02-12
发明人： FOLEY, Louise, Helen , HUBY, Nicholas, John, Silvester , PIETRANICO-COLE, Sherrie, Lynn , YUN, Weiya , DUNTEN, Pete, William
IPC分类号： C07D473/04 , A61K31/52 , A61P3/10
CPC分类号： C07D473/04 , C07D473/06 , C07D473/08
摘要： The present invention is concerned with sulfonamide substituted xanthine derivatives of formula (I) or a pharmaceutically acceptable salts or prodrugs thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
摘要翻译： 本发明涉及式（I）的磺酰胺取代的黄嘌呤衍生物或其药学上可接受的盐或前药，其中R 1，R 2和R 3如说明书中所定义。 式（I）化合物及其药学上可接受的盐或前药显示出作为糖异生的调节剂的活性。
-
7.发明公开AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY 有权阿米德黄嘌呤糖异生调控作用取代衍生物
公开(公告)号：EP1515972A1
公开(公告)日：2005-03-23
申请号：EP03735559.1
申请日：2003-06-05
发明人： DUNTEN, Pete, William , FOLEY, Louise, Helen , HUBY, Nicholas, John, Silvester , PIETRANICO-COLE, Sherrie, Lynn , YUN, Weiya
IPC分类号： C07D473/02 , A61K31/52 , A61P3/10
CPC分类号： C07D473/04 , C07D473/02 , C07D473/06
摘要： The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R , R and R are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
-
公开(公告)号：EP1781649B1
公开(公告)日：2008-08-13
申请号：EP05771890.0
申请日：2005-08-09
发明人： CHU, Xin-Jie , FOTOUHI, Nader , HUBY, Nicholas, John, Silvester , KONG, Norman , MCDERMOTT, Lee, Apostle , MOLITERNI, John, Anthony , ZHANG, Zhuming
IPC分类号： C07D417/12 , C07D417/14 , A61K31/427
CPC分类号： C07D417/12 , C07D417/14
摘要： The present invention relates to compounds of the formula (I), which are useful in treating diseases characterized by, the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
-
9.发明公开SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS 有权SULFONAMIDSUBSTITUIERTE克桑西衍生物FOR USE AS PEPCK抑制剂
公开(公告)号：EP1599477A1
公开(公告)日：2005-11-30
申请号：EP04710346.0
申请日：2004-02-12
发明人： FOLEY, Louise, Helen , HUBY, Nicholas, John, Silvester , PIETRANICO-COLE, Sherrie, Lynn , YUN, Weiya , DUNTEN, Pete, William
IPC分类号： C07D473/04 , A61K31/52 , A61P3/10
CPC分类号： C07D473/04 , C07D473/06 , C07D473/08
摘要： The present invention is concerned with sulfonamide substituted xanthine derivatives of formula (I) or a pharmaceutically acceptable salts or prodrugs thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
